Immutep

IMMP

Market cap $57.3M

SYDNEY, AUSTRALIA, July 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced a significant positive update of the investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alfa (efti) in combination with MSD's (Merck & Co. Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and chemotherapy as 1st line therapy for advanced/metastatic non-small cell lung cancer (1L NSCLC) in 51 evaluable non-squamous patients.

LOS ANGELES, July 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of IMMP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

LOS ANGELES--(BUSINESS WIRE)---- $IMMP--IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm.

LOS ANGELES, July 02, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immutep Limited (“Immutep” or “the Company”) (NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 24, 2025 and March 12, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before July 6, 2026.

NEW YORK, July 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP) investors of the July 6, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Immutep Class Action Lawsuit : Do you, or did you, own shares of Immutep Limited (NASDAQ: IMMP)?

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP).   Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

LOS ANGELES, June 30, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Immutep Limited, (“Immutep” or the "Company") (NASDAQ: IMMP) investors of a class action on behalf of investors that bought securities between March 24, 2025 and March 12, 2026, inclusive (the “Class Period”). Immutep investors have until July 6, 2026 to file a lead plaintiff motion.

San Diego, California--(Newsfile Corp. - June 29, 2026) - Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug Candidate On May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases.

LOS ANGELES, June 29, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of IMMP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.